Cargando…

The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus

The treatment strategy in relapsing multiple sclerosis (RMS) is a complex decision requiring individualization of treatment sequences to maximize clinical outcomes. Current local and international guidelines do not provide specific recommendation on the use of immune reconstitution therapy (IRT) as...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Sèze, Jerome, Suchet, Laurent, Mekies, Claude, Manchon, Eric, Labauge, Pierre, Guennoc, Anne-Marie, Defer, Gilles, Clavelou, Pierre, Castelnovo, Giovanni, Bourre, Bertrand, Bensa-Koscher, Caroline, Al Khedr, Abdullatif, Le Mao, Julie, Villemur, Lauriane, Bouée, Stephane, Luciani, Laura, Vermersch, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043116/ https://www.ncbi.nlm.nih.gov/pubmed/36564664 http://dx.doi.org/10.1007/s40120-022-00430-z

Ejemplares similares

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
por: Brochet, Bruno, et al.
Publicado: (2022)

Inflammatory-like presentation of CADASIL: a diagnostic challenge
por: Collongues, Nicolas, et al.
Publicado: (2012)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
por: Lebrun-Frénay, Christine, et al.
Publicado: (2021)

Treatment satisfaction and quality of life in patients treated with fingolimod
por: Mékiès, Claude, et al.
Publicado: (2018)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
por: Tourbah, Ayman, et al.
Publicado: (2018)

Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
por: Wilson, Sarah, et al.
Publicado: (2022)

DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
por: Sormani, Maria Pia, et al.
Publicado: (2021)

Tardive Reactivation of Progressive Multiple Sclerosis During Treatment with Biotin
por: Demas, Alexis, et al.
Publicado: (2019)

An observational study of the initial management of hypothyroidism in France: the ORCHIDÉE study
por: Delemer, Brigitte, et al.
Publicado: (2012)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
por: Leray, Emmanuelle, et al.
Publicado: (2015)

Bedside Tested Ocular Motor Disorders in Multiple Sclerosis Patients
por: Servillo, G., et al.
Publicado: (2014)

A MANBA mutation resulting in residual beta-mannosidase activity associated with severe leukoencephalopathy: a possible pseudodeficiency variant
por: Sabourdy, Frédérique, et al.
Publicado: (2009)

‘Comment on Saumitou et al. (2017): Elucidation of the genetic architecture of self‐incompatibility in olive: evolutionary consequences and perspectives for orchard management’
por: Breton, Catherine, et al.
Publicado: (2017)

Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France
por: Pourcher, Valérie, et al.
Publicado: (2020)

Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis
por: Neuzillet, Cindy, et al.
Publicado: (2022)

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France
por: Pivot, Diane, et al.
Publicado: (2016)

Species- and site-specific circulating bacterial DNA in Subantarctic sentinel mussels Aulacomya atra and Mytilus platensis
por: Ferchiou, Sophia, et al.
Publicado: (2022)

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies
por: Maillart, Elisabeth, et al.
Publicado: (2020)

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation
por: Stern, Lauren, et al.
Publicado: (2018)

Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study
por: Veziris, Nicolas, et al.
Publicado: (2021)

Reply to Saumitou‐Laprade et al. (2017) “Controlling for genetic identity of varieties, pollen contamination and stigma receptivity is essential to characterize the self‐incompatibility system of Olea europaea L.”. Eva:https://doi.org/10.1111/eva.12498
por: Farinelli, Daniela, et al.
Publicado: (2018)

Specific lumbar puncture training during clinical clerkship durably increases atraumatic needle use
por: Moisset, Xavier, et al.
Publicado: (2019)

Multiple sclerosis as differential diagnosis of radionecrosis for post-irradiation brain lesions: A case report
por: Guillemin, Florent, et al.
Publicado: (2020)

Insights into the circulating microbiome of Atlantic and Greenland halibut populations: the role of species-specific and environmental factors
por: Fronton, Fanny, et al.
Publicado: (2023)

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
por: Branger, Pierre, et al.
Publicado: (2016)

Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease
por: Cobo-Calvo, Alvaro, et al.
Publicado: (2019)

Ancestral population reconstitution from isofemale lines as a tool for experimental evolution
por: Nouhaud, Pierre, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database
por: Bouée, Stéphane, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_letkr2iep6dtv6aa87eo2usbaa